More evidence points to the benefits of germline genetic testing for patients with various cancers. Such testing can identify mutations that may warrant a change of treatment and allow trying a ...
This qualitative interview study enrolled patients diagnosed with prostate cancer who had been treated at a safety-net hospital and had received a referral for genetic testing in the previous 12 ...
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...
A study of three genes associated with the development of prostate cancer found that men with inherited mutations in these genes are more likely to develop aggressive forms of the disease and die from ...
Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...
MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, announced a new analysis has been published in the Journal of Health Economics and Outcomes ...
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the ...
The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of adults with a deleterious BRCA mutation (germline and/or ...
Hereditary breast cancer results from inherited mutations, primarily in BRCA1 and BRCA2, increasing lifetime cancer risk. Additional genes like TP53, PTEN, PALB2, CHEK2, and ATM also contribute to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback